Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Published in: Annals of Hematology 2/2013

01-02-2013 | Letter to the Editor

Intravascular large B cell lymphoma presenting as anasarca: an unusual presentation of a rare lymphoma

Authors: Narat Srivali, Kunatum Prasidthratsint, Nischala Ammannagari, Wisit Cheungpasitporn, Patompong Ungprasert

Published in: Annals of Hematology | Issue 2/2013

Login to get access

Excerpt

Dear Editor, …
Literature
1.
Shimada K, Matsue KS, Yamamoto K et al (2008) Retrospective analysis of intravascular large B-cell lymphoma treated with rituximab-containing chemotherapy as reported by the IVL study group in Japan. J Clin Oncol 26:3189–3195PubMedCrossRef
2.
Pfleger L, Tappeiner J (1959) On the recognition of systematized endotheliomatosis of the cutaneous blood vessels (reticuloendotheliosis?). Hautarzt 10:359–363PubMed
3.
Wick MR, Mills SE, Scheithauer BW, Cooper PH, Davitz MA, Parkinson K (1986) Reassessment of malignant “angioendotheliomatosis”. Evidence in favor of its reclassification as “intravascular lymphomatosis”. Am J Surg Pathol 10:112–123PubMedCrossRef
4.
Nakamura S, Ponzoni M, Campo E et al (2008) Intravascular large B-cell lymphoma. In: Swerdlow SH, Campo E, Harris NL (eds) WHO classification of tumours of haematopoeitic and lymphoid tissues. IARC, Lyon, pp 252–253
5.
Ferreri AJ, Campo E, Seymour JF et al (2004) Intravascular lymphoma: clinical presentation, natural history, management and prognostic factors in a series of 38 cases, with special emphasis on the ‘cutaneous variant’. Br J Haematol 127:173–183PubMedCrossRef
6.
Shimada K, Kinoshita T, Naoe T, Nakamura S (2009) Presentation and management of intravascular large B-cell lymphoma. Lancet Oncol 10:895–902PubMedCrossRef
7.
Matsue K, Asada N, Odawara J et al (2011) Random skin biopsy and bone marrow biopsy for diagnosis of intravascular large B cell lymphoma. Ann Hematol 90:417–421PubMedCrossRef
8.
Ferrari AJ, Dognini GP, Govi S et al (2008) Can rituximab change the usually dismal prognosis of patient with intravascular large B-cell lymphoma? J Clin Oncol 26:5134–5137CrossRef
Metadata
Title
Intravascular large B cell lymphoma presenting as anasarca: an unusual presentation of a rare lymphoma
Authors
Narat Srivali
Kunatum Prasidthratsint
Nischala Ammannagari
Wisit Cheungpasitporn
Patompong Ungprasert
Publication date
01-02-2013
Publisher
Springer-Verlag
Published in
Annals of Hematology / Issue 2/2013
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-012-1548-5

Other articles of this Issue 2/2013

Annals of Hematology 2/2013 Go to the issue

Original Article

Efficacy and safety of deferasirox at low and high iron burdens: results from the EPIC magnetic resonance imaging substudy

Review Article

Strategies of pain reduction during the bone marrow biopsy

Original Article

KIT D816 mutation associates with adverse outcomes in core binding factor acute myeloid leukemia, especially in the subgroup with RUNX1/RUNX1T1 rearrangement

Letter to the Editor

Renal failure secondary to leukemic infiltration of kidneys in CLL—a case report and review of literature

Letter to the Editor

Nephrolithiasis in beta thalassemia major patients treated with deferasirox: an advent or an adverse event? A single Greek center experience

Original Article

Allogeneic hematopoietic stem cell transplantation for patients with mildly reduced renal function as defined based on creatinine clearance before transplantation
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits